HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital (H-Cov-Run)
2022年8月29日 更新者:Centre Hospitalier Universitaire de la Réunion
Since December 2019, the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic has spread around the world.
The people most exposed to this virus remain the healthcare personnel who are on the front line in the fight against this pandemic.
Due to the delayed nature of the pandemic in Reunion island and its insular geographical situation, the study of the voluntary medical personnel will allow the investigators to establish a longitudinal follow-up of the anomalies of the lipidic balance in relation to the exposure to the SARS-Cov virus.
2. During bacterial infections, the lipid profiles are profoundly modified with very significant reductions in plasma cholesterol levels, LDL-C but especially HDL-C whose concentrations are particularly low.
Lipid profiles are altered during viral infections, for example, the severity of dengue is inversely correlated with total cholesterol and LDL-C but not with HDL-C levels, according to a recent meta-analysis.
The hepatitis C virus circulates in serum linked to lipoproteins rich in triglycerides and HDL can facilitate its entry into cells via Scavenger receptor class B type 1 (SRB1).
Likewise, it has been shown that apoA1 can bind to the dengue virus and increase its infectivity by promoting its entry into cells, also via SRB1.
At the moment, nothing is known about the lipid profiles in subjects with SARS-CoV-2.
The investigator hypothesize that a drop in plasma HDL-C levels and a change in their size during infection could justify future therapeutic approaches aimed at supplementing the subjects most at risk of pulmonary complications.
In a model of Pseudomonas aeruginosa pneumonia in mice, investigators have shown that the injection of reconstituted HDL allowed to limit the pulmonary inflammation and the deleterious consequences of the infection.
The investigator propose to study not only the lipid profiles in subjects who are infected with SARS-CoV-2 but also the polymorphisms of genes involved in the regulation of lipoprotein levels like that of Cholesterol Ester-Transfer Protein (CETP) depending on the developed forms, symptomatic or not.
研究概览
研究类型
观察性的
注册 (实际的)
361
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Saint-Denis、法国、97400
- Centre Hospitalier Universitaire Réunion
-
Saint-Pierre、法国、97448
- Centre Hospitalier Universitaire de La Réunion
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Caregiver in Reunion island University Hospital Center who practice in a care service possibly exposed to the coronavirus
描述
Inclusion Criteria:
- Caregiver in Reunion island University Hospital Center
- Practicing in a care service possibly exposed to the coronavirus
- Signed Consent
Exclusion Criteria:
- Refusal to participate
- Already infected by Covid19
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 观测模型:队列
- 时间观点:预期
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
caregivers
|
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change of lipid profile during exposure to SARS-Cov-2
大体时间:at the end of the study, maximum 1 year
|
lipid profile
|
at the end of the study, maximum 1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
HDL-cholesterol size
大体时间:at the end of the study, maximum 1 year
|
HDL-cholesterol size
|
at the end of the study, maximum 1 year
|
|
circulating plasma cytokine levels
大体时间:at the end of the study, maximum 1 year
|
circulating plasma cytokine levels
|
at the end of the study, maximum 1 year
|
|
ACE2 gene polymorphisms
大体时间:at the end of the study, maximum 1 year
|
ACE2 gene polymorphisms
|
at the end of the study, maximum 1 year
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2020年6月17日
初级完成 (预期的)
2023年9月1日
研究完成 (预期的)
2023年9月1日
研究注册日期
首次提交
2020年5月6日
首先提交符合 QC 标准的
2020年5月11日
首次发布 (实际的)
2020年5月12日
研究记录更新
最后更新发布 (实际的)
2022年8月30日
上次提交的符合 QC 标准的更新
2022年8月29日
最后验证
2022年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.